Journal of Magnetic Resonance Imaging

Objective: To demonstrate the proof of principle that machine learning (ML) can be used to quantify Gleason Pattern (GP) 4 on digitized biopsy slides using multiple measurement approaches, allowing direct comparison of their prognostic performance. Methods: We assembled a convenience sample of 726 patients with grade group 2-4 prostate cancer on systematic biopsy who underwent radical prostatectomy between 2014 and 2023. Digitized biopsy slides were analyzed using a machine-learning algorithm (PAIGE-AI) to quantify GP4 using multiple measurement approaches, particularly with respect to how gaps between cancer foci (interfocal stroma) were handled. GP4 extent was quantified using linear measurements or a pixel-based area metric. Discrimination of each GP4 quantification approach, along with Grade Group (GG), was assessed for adverse radical prostatectomy pathology and biochemical recurrence. Results: We identified 15 different quantification approaches and observed differences between their discrimination. The highest discrimination was in the pixel-counting method (AUC 0.648). GP4 quantification outperformed GG for predicting adverse pathology (AUC 0.627 vs 0.608). Amount of GP3 was non-predictive once GP4 was known. These findings were consistent for BCR. Conclusions: We were able to measure slides using 15 distinct measurement approaches and replicated prior findings using ML to quantify GP4. Our findings support the use of ML as a research tool to compare different GP4 quantification approaches. We intend to use our method on larger cohorts to determine with which measurement approach best predicts oncologic outcome.

Focal cortical dysplasias (FCDs) are one of the most common structural causes of drug-resistant epilepsy in children but are frequently subtle and difficult to detect on conventional MRI. Many automated lesion detection methods have therefore been proposed to support neuroradiological assessment. In this study, we externally validated two recently developed deep-learning approaches for FCD detection, MELD Graph and 3D-nnUNet, in a pediatric cohort. In this retrospective single-center study, brain MRI scans of 71 children evaluated for epilepsy were analyzed, including 35 MRI-positive patients with suspected FCD and 36 MRI-negative cases based on the primary radiology reports. Both models were applied to standard 3D T1-weighted and 3D FLAIR images. Detected lesions were reviewed by an experienced pediatric neuroradiologist and classified as true positive, false positive, or false negative. Clinical semiology and EEG findings were additionally evaluated for cases with false-positive detections. At the lesion level, MELD Graph achieved a precision of 0.85 and recall of 0.52, while 3D-nnUNet achieved a precision of 0.91 and recall of 0.48. In the MRI-negative patients, MELD Graph produced more false-positive detections than 3D-nnUNet (0.53 vs. 0.14 false-positive lesions per patient). At the patient level, MELD Graph showed slightly higher sensitivity than 3D-nnUNet (0.63 vs. 0.54), whereas 3D-nnUNet demonstrated markedly higher specificity (0.86 vs. 0.56). Improved FLAIR image quality was associated with trends toward improved model performance. Both models demonstrated high precision but moderate sensitivity, indicating that they are valuable decision-support tools but cannot replace expert neuroradiological evaluation. Optimized MRI acquisition protocols are needed to further improve automated lesion detection in pediatric epilepsy.

Background. Breast cancer (BC) remains the most diagnosed malignancy and leading cancer-related cause of mortality in women worldwide. Although blood-based untargeted metabolomics has emerged as a promising modality for detecting early-stage BC, the clinical translation of this approach has been bottlenecked by two unresolved issues: (i) the field has almost exclusively relied on serum or plasma, which require venipuncture and cold-chain logistics, and (ii) machine-learning models reported on such data are frequently validated with protocols that are blind to analytical batch structure, producing optimistically biased performance estimates. Methods. We present a breast cancer detection study based on dried blood spots (DBS), an analytical matrix that enables self-collection and ambient-temperature shipping. A cohort of 2,734 participants (114 biopsy-confirmed BC cases; 2,620 non-cancer controls) was profiled by untargeted LC-MS/MS on a Thermo Scientific Orbitrap IQ-X coupled to a Vanquish UHPLC. A 39-metabolite panel meeting MSI Level 1 identification criteria was pre-specified a priori from the published breast-cancer metabolomics literature, frozen prior to LC-MS acquisition, and applied to the present cohort without any feature selection on the data. Six standard supervised-learning architectures (LASSO, Elastic Net, Linear SVM, PLS-DA, OPLS-DA, XGBoost) were evaluated on this pre-specified panel; OPLS-DA is reported only in the sex-matched subgroup analysis where a single-seed 5-fold stratified protocol permits a directly comparable fit. Per-batch control-median normalization is applied upstream; kNN imputation, log transform, and robust scaling are fit within each training fold. The evaluation battery comprises batch-aware StratifiedGroupKFold CV at single-seed (seed=42) with inter-seed SD quantified across 10 independent seeds, batch-aware nested CV, a 100-seed held-out 20%-batch validation with disjoint-batch isotonic probability calibration (30% calibration partition), PPV/NPV reporting at multiple operating points and three deployment prevalences, subgroup analyses by TNM stage and tumor grade, pathway-ablation sensitivity analysis, and a 1,000-iteration permutation test. Results. Under batch-aware evaluation (StratifiedGroupKFold, single-seed=42), AUC ranged from 0.914 to 0.949 across classifiers, with LASSO achieving 0.928 and XGBoost 0.949; inter-seed SD across 10 seeds was 0.002-0.006. At 95% specificity, LASSO reached 75.4% sensitivity and XGBoost 81.6%. Held-out batch validation (100 seeds) yielded mean AUC 0.912 for Elastic Net and 0.935 for XGBoost, confirming robust generalization. All 39 panel features showed high coefficient stability, and permutation testing on representative classifiers (LASSO, Linear SVM, PLS-DA) yielded p <= 0.001. Subgroup analyses showed weaker detection of stage IIA tumors (AUC 0.87, n=40) compared with stage IIB/IIIA (AUC 0.95), consistent with stronger metabolic signatures in more advanced disease. Bootstrap coefficient consistency of the Elastic Net classifier confirmed that all 39 panel features received a non-zero multivariate weight in >=80% of 100 stratified bootstraps. Conclusions. On this cohort of diagnosed, pre-treatment breast-cancer cases, DBS LC-MS metabolomic profiling delivers classification performance (AUC 0.928 for LASSO and 0.949 for XGBoost under batch-aware GroupKFold CV at single-seed=42; held-out AUC 0.912-0.935) that is robust across classifier families and biological pathways. The DBS matrix is non-radiating, self-collectable by finger-prick, and mailable at ambient temperature. Performance is weaker on stage IIA than on more advanced disease, and prospective validation in an independent asymptomatic screening cohort is required before clinical positioning as a decentralized triage modality.

Background: Medical imaging, especially computed tomography and magnetic resonance imaging, is essential in clinical care of patients with renal cell carcinoma (RCC). Artificial intelligence (AI) research into computer-aided diagnosis, staging and treatment planning needs curated and annotated datasets. Across literature, The Cancer Genome Atlas (TCGA) datasets are widely used for model training and validation. However, re-annotation is often necessary due to limited access to public annotations, raising entry barriers and hindering comparison with prior work. Methods: We screened 1915 CT scans from three TCGA-RCC databases and employed a segmentation model to annotate kidney lesion. After a meta-data-based exclusion step, we hosted a reader study with all papillary (n=56), chromophobe (n=27) and 200 randomly selected clear cell RCC cases. Two students quality checked and corrected the data as well as annotated tumors and cysts. Uncertain cases were checked by a board-certified radiologist. Results: After data exclusion and quality control a total of 142 annotated CT scans from 101 patients (26 female, 75 male, mean age 56 years) remained. This includes 95 CTs with clear cell RCC, 29 with papillary RCC and 18 with chromophobe RCC. Images and voxel-level annotations of kidneys and lesions are open sourced at https://zenodo.org/records/19630298. Conclusion: By making the annotations open-source, we encourage accessible and reproducible AI research for renal cell carcinoma. We invite other researchers who have previously annotated any of these cohorts to share their annotations.

This research demonstrates that the trans-aqueduct approach is a feasible, minimally invasive access pathway to the third ventricle, offering a potential route to the deep brain for therapeutic technologies. Further pre-clinical investigation is required to thoroughly evaluate physiological tolerance, trauma risk, and the long-term implications of intraventricular implantation. The third ventricle is a high-value site for neuromodulation due to its proximity to deep-brain targets, including the subthalamic nucleus (STN) and globus pallidus internus (GPi). This study defined the anatomical pathway; and evaluated the technical feasibility of retrograde access to the third ventricle via the cerebral aqueduct using minimally invasive interventional techniques. Evaluation was conducted in three phases using human MRI datasets (n=16; mean age 48.4 years) and cadaveric specimens (n=6; mean age 88.2 years). Phase 1 involved morphometric MRI analysis of the aqueduct and ventricles. Phase 2 tested trans-aqueduct access on cadaver specimens via fluoroscopically guided guidewires and catheters. Phase 3 utilized direct anatomical dissections on cadaver specimens (n=3) to morphometrically measure the third ventricular cavity and its relationship to deep-brain nuclei. Measurements across the sample groups showed a mean aqueduct diameter of 1.6 mm (SD=0.14). Third ventricle dimensions averaged 27.6 mm (ventral-dorsal), 19.9 mm (caudal-cranial), and 5.7 mm (lateral). Successful access to the third ventricle was achieved in 83% (5/6) of cadaveric specimens. The optimal technical configuration utilized a 0.018'' angled-tip guidewire and 5-6 Fr catheters; the aqueduct accommodated diameters up to 2.0 mm with minimal resistance. The STN and GPi were localized within 5-20 mm of the ventricular volumetric centroid. The trans-aqueduct approach is a technically feasible, minimally invasive pathway for accessing the third ventricle. This route offers a potential alternative for the delivery of therapeutic neurotechnologies. Further research is required to assess physiological tolerance, trauma risk, and the long-term safety of intraventricular implantation.

Objective and RationaleBrain biomechanics is a rapidly evolving field, with mechanical properties influencing both normal development and pathological conditions such as cancer. Brillouin microscopy, a non-contact optical technique, offers a promising approach for studying the biomechanics of fresh brain tumors and organoids at subcellular resolution. However, challenges such as tissue heterogeneity and signal attenuation necessitate an in-depth evaluation of measurement strategies and potential confounding factors. MethodsFresh human brain tumor samples and tumor organoids were analyzed using Brillouin microscopy with 780 nm excitation. Measurements in the form of maps of various size were performed, and the impact of focal position, tissue heterogeneity and blood contamination on Brillouin data was assessed. Complementary Raman spectroscopy was performed as reference for tissue composition. ResultsBrillouin signal intensity decreased exponentially with depth, with valid measurements achievable up to 80 {micro}m. Low signal intensities at greater depths compromised data reliability due to fitting algorithm limitations. Structural heterogeneity, including different cell types, differentially affected signal attenuation. Blood contamination was identified as a major confounder, leading to erroneous biomechanical readings. Brillouin intensity maps provided essential quality control for accurate data interpretation. Raman spectroscopy identified the presence of blood and tissue-specific biochemical signatures, reinforcing the importance of multimodal analysis. ConclusionsBrillouin microscopy can effectively probe biomechanical properties of fresh brain tumors but is influenced by tissue heterogeneity and contaminants. Proper sample preparation, strategic focal positioning, and complementary techniques like Raman spectroscopy are critical for ensuring reliable data. These findings contribute to refining Brillouin microscopy protocols for neuro-oncological research and potential future clinical applications.

IntroductionColorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, despite advances in conventional oncological therapies. In recent years, various studies have made advances in integrative oncology, such as investigating the use of Chinese Herbal Medicine (CHM) as a complementary therapy alongside conventional oncological therapies to alleviate treatment-related adverse effects, improve quality of life, and potentially enhance therapeutic outcomes. Despite this, clinical practice in this area remains highly heterogeneous, with limited standardized guidelines on key areas of concern such as (1) optimal intervention, (2) recommended stage and duration of intervention, (3) safety considerations, and (4) possible herb-drug interactions. Hence, this study aims to establish expert consensus on the usage of CHM as a complementary therapy in the management of CRC, to support safe, consistent, and evidence-informed clinical practice. Methods and AnalysisWe will employ a modified Delphi technique to achieve consensus amongst a panel of international experts in various fields related to integrative oncology. Prior to the study, a list of questionnaire items was developed based on a systematic review of existing clinical practice guidelines on CRC. An international panel will be invited based on established international profile in integrative oncology research and clinical practice, and by peer referral. Two rounds of Delphi will be conducted using anonymous online questionnaires. Consensus will be considered reached if at least 50% of the panel strongly agree/disagree that an item should be included or excluded while strong consensus will be set at 76%. Items which achieve strong consensus after Round 1 will be removed, before being sent out for Round 2 with a summary of Round 1 responses for a final consensus. Ethics and DisseminationEthics approval has been obtained from the Institutional Review Board of Nanyang Technological University (IRB-2025-1222). Our findings will be disseminated through peer-reviewed publications and conference presentations. Strengths and limitations of this studyO_LIThis study will develop an expert consensus which aims to guide future integration of Chinese Herbal Medicine (CHM) as a complementary therapy into colorectal cancer (CRC) management. C_LIO_LIKey concerns in areas such as determining the (1) optimal intervention, (2) recommended stage and duration of intervention, (3) safety considerations, and (4) possible herb-drug interactions, thereby laying the groundwork for potential future incorporation of CHM into CRC treatment protocols alongside conventional oncology approaches has been identified, thus limiting implementation in clinical practice. C_LIO_LIDesigning a study e-guide, followed by the consensus rounds study online will facilitate participants responses and the dissemination of information from previous rounds. C_LI

Quantitative microstructural magnetic resonance imaging (MRI) can noninvasively characterize tissue configuration at micrometer scales, but clinical uptake is limited by validation and optimization in human-relevant scenarios. Organoids are powerful human-relevant tissue models, yet translation is hampered by lack of non-destructive, longitudinal microstructural assessment. Bridging these gaps, microstructural MRI of living organoids can accelerate MRI biomarker and organoid development and validation. Here, we address key obstacles to enable organoid microstructural MRI. First, we use a unique 28.2 T MRI system to achieve spatial resolution with adequate signal-to-noise ratio and feasible scan times. Second, we implement flexible acquisitions with fast readouts to expand multivariate experimental capacity. Third, we develop a workflow combining 3D MRI and 3D lightsheet microscopy for cross-modality anatomical comparison beyond 2D. Using this platform, we demonstrate microstructural MRI of cortical organoids with resolutions down to (20 {micro}m)3, revealing anisotropy, heterogeneity, maturation-dependent differences, and temporal changes in cortical organoids. Correlative lightsheet microscopy confirms correspondence to axonal and nuclear architecture. This platform enables live-organoid MRI as a complementary tool to human- and animal imaging for robust microstructural assessment.

Abstract: Purpose: Recurrence in high grade glioma (HGG) predominantly occurs within the high dose radiation field, raising the question of whether treatment failure reflects limitations in radiation target delineation or is driven by intrinsic tumor biology. This study evaluated recurrence patterns following standard chemoradiotherapy and their treatment implications. Material and Methods: This retrospective single center study included 41 patients with histologically confirmed HGG treated with surgery followed by radiotherapy with concurrent and adjuvant temozolomide (TMZ). Patients were followed through August 2018; those with recurrence were included in the analysis. Recurrence patterns were classified based on their spatial relationship to the 60 Gy isodose line as central, infield, marginal, or distant. Survival outcomes were estimated using the Kaplan-Meier method and compared using the log rank test. Results: The most common pattern of recurrence was central (15 patients, 36.5%), followed by infield (11, 26.8%), distant (6, 14.6%), marginal (5, 12.1%), and multicentric (4, 9.8%). Central and in field recurrences (local failures) accounted for 26 patients (63%). Median overall survival (OS) was 27 months, and median progression-free survival (PFS) was 12 months. Survival differed significantly by recurrence pattern (log-rank p = 0.018), with marginal recurrence associated with more favorable outcomes. Conclusion: The predominance of central and infield recurrences within the high-dose region suggests that treatment failure in HGG is not solely explained by inadequate target delineation and may also be driven, in part, by intrinsic tumor biology, including radioresistant subpopulations and tumor heterogeneity. Future strategies may benefit from incorporating biologically guided approaches alongside optimization of radiation treatment parameters.

Early detection of breast cancer remains essential for improving clinical outcomes, and complementary non-invasive approaches are needed to support existing screening methods, particularly for women with dense breast tissue. We have previously reported plasma lipid biomarker discovery using untargeted high-resolution liquid chromatography tandem mass spectrometry (LC-MS/MS). In this study, we performed biomarker confirmation and developed machine-learning models applied to targeted plasma lipid measurements for the non-invasive detection of early-stage breast cancer across international cohorts with independent external validation. Targeted LC-MS/MS was used to quantify candidate lipid panels in plasma samples from European discovery cohorts (n = 554) and an independent Australian cohort (n = 266) used for external validation. Data-driven feature selection identified a 15-lipid panel with strong performance in European cohorts (AUC >= 0.94). External validation prior to confidence stratification yielded 76% sensitivity, 64% specificity, and an AUC of 0.81 in the Australian validation cohort. Clinical assay development requires iterative panel and model testing to support translational feasibility and performance in the intended-use population. An analytically viable panel, excluding lipids requiring complex and costly synthesis, achieved comparable accuracy with improved assay robustness. Confidence-based analysis showed enhanced performance for predictions made with moderate to high confidence, with sensitivity up to 89% and AUC up to 0.85, suggesting that ongoing research should focus on strategies to enhance diagnostic model confidence. Importantly, model predictions were independent of breast density, tumour size, grade, subtype, and morphology, indicating biological specificity of the lipid signature. These results demonstrate that calibrated machine-learning models applied to plasma lipid biomarkers can support non-invasive breast cancer detection. Expanding training datasets to include greater diversity will further improve performance in the ongoing development of this lipid-based detection approach.

Accurate histopathological differentiation between High-Grade Serous Carcinoma (HGSC) and Low-Grade Serous Carcinoma (LGSC) remains a critical yet challenging aspect of ovarian cancer diagnosis due to their similar morphology and different clinical outcomes. This study presents a deep learning framework that uses custom attention mechanisms, including the Convolutional Block Attention Module (CBAM), Squeeze-and-Excitation (SE) blocks, and a Differential Attention module within five CNN architectures for automated binary classification of ovarian cancer subtypes from H&E WSI patches. Although individual models achieved higher accuracy, the ensemble stacking framework with a shallow MLP meta-learner delivered the best overall performance, with a ROC-AUC of 0.9211, an accuracy of 0.85, and F1-scores of 0.84 and 0.85 across both subtypes. These findings demonstrate that attention-guided feature recalibration combined with ensemble stacking provides robust and clinically interpretable discrimination of ovarian carcinoma subtypes.

We investigate the effects of skin pigmentation and light source characteristics on the performance of reflective Pulse oximetry (PO) devices used in healthcare and well-being applications. We use Monte Carlo (MC) simulations to compare ideal monochromatic and realistic LED spectral emission profiles and tolerance-related wavelength shifts. The simulation covers photon transport in skin models with melanin concentrations (2.55% to 30.5%) and arterial oxygen saturations SaO2 (70% to 100%.) Accuracy was assessed by SpO2 error, root-mean-square error RMSE (Arms), and percentile tail-errors (P90, P95, and P99). Monochromatic spectral emission yielded the lowest SpO2 error (RMSE = 1.32), while LED spectral emission profiles increased errors (RMSE = 2.10). Infrared wavelength tolerances increased SpO2 RMSE by 1.1 {+/-} 0.3. SpO2 error increased with melanin concentration, from underestimation (-1.8 {+/-} 0.1%) at 2.55% melanin concentration to overestimation (+3.9 {+/-} 1.2%) at 30.5% for low SaO2 (70%) and LED spectral emission profiles. At 30.5% melanin concentration, P95 and P99 exceeded FDA and DIN EN ISO 80601-2-61 thresholds, in particular at low SaO2 (70%). Clipping SpO2 estimates at 100% resulted in an apparent RMSE decrease of up to 3%, reflecting error masking rather than real error reduction. In conclusion, LED spectral emission profiles and wavelength tolerances can amplify melanin-related bias in SpO2 estimates. Monochromatic emission and tighter wavelength control can reduce SpO2 error and should be considered in device design and regulation. Regulatory standards should discourage clipping SpO2 estimates at 100% and mandate additional metrics as RMSE fails to reflect clinically critical percentile error thresholds, i.e. P95 and P99.

Harmonisation is widely used to mitigate site- and scanner-related batch variability in multisite neuroimaging studies and is particularly critical in longitudinal clinical trials, where detection of subtle biological or treatment-related changes depends on reliable measurement across scanners and timepoints. However, the effectiveness of harmonisation in small, heterogeneous clinical datasets remains insufficiently understood, particularly in relation to subject-level variability and consistency across acquisition settings, and its impact on both removal of technical variability and preservation of biological variation in pooled multisite analyses. We systematically evaluated a range of image-based and statistical harmonisation methods using a clinically realistic multisite, multiscanner structural T1-weighted (T1w) MRI test-retest dataset comprising three controlled acquisition scenarios: repeatability, intra-scanner reproducibility and inter-scanner reproducibility. Methods were applied under different batch specifications (site, scanner, or both) and performance was assessed within each scenario and in pooled data using a multi-metric framework capturing both technical and biological variability in volumetric imaging-derived phenotypes (IDPs) relevant to aging and dementia research. Across IDPs, before harmonisation variability was lowest in the repeatability scenario (median variability=0.6 to 2.7%, rank consistency {rho} [&ge;]0.9), with modest increases under intra-scanner reproducibility (0.5 to 3.2%, {rho}=0.5 to 1.0) and substantially greater variability under inter-scanner reproducibility conditions (1.7 to 19.2%, {rho} =-0.1 to 0.9). These results offer important information to consider for multisite study design, including sample size calculation in clinical trials. Harmonisation performance was strongly context dependent, with clearer benefits emerged in inter-scanner scenarios where both variability reduction and improvements in subject-level consistency were observed. In pooled data, approaches that explicitly modelled site as batch and accounted for repeated-measure structure showed greater consistency across IDPs in batch effect mitigation and more accurately reflected underlying biological variation. Our evaluation metrics enabled disentangling the removal of global batch effect while highlighting residual variability at the phenotype-specific or multivariate levels. These findings demonstrate that harmonisation cannot be treated as a one-size-fits-all solution and must be interpreted relative to the acquisition context, dataset structure, and downstream analytic goals. Multi-metric evaluation under realistic clinical constraints is essential to support reliable and translatable neuroimaging inference by ensuring appropriate correction of batch effects while preserving longitudinal biological signals and sensitivity to clinically meaningful change in multisite studies.

INTRODUCTIONAlzheimers disease (AD) manifests a specific spatial progression pattern, but its propagation mechanisms remain unclear. METHODSWe employed nine brain connectomes spanning multiple biological levels to investigate the mechanisms underlying cortical atrophy propagation in AD. Individual gray matter atrophy maps were quantified using normative modeling and were then mapped onto the connectomes by assessing the relationship between regional atrophy and the atrophy of neighboring regions defined by each connectome. RESULTSCross-sectionally, node-neighbor relationship was weak in the preclinical stage, suggesting limited influence of connectome architecture. Longitudinally, atrophy became progressively more aligned with the neurotransmitter receptor similarity connectome in individuals with MCI converting to AD dementia and dementia patients. DISCUSSIONOur findings described a stage-dependent shift in cortical atrophy propagation, with neurotransmitter receptor similarity playing an increasing role as AD progresses.

Purpose: To develop an interpretable feature-based Deep Parametric Response Mapping (PRMD) method that combines wavelet scattering convolution networks and machine learning to spatially detect and quantify functional small airways disease (fSAD) and emphysema on paired inspiratory-expiratory CT scans, with enhanced noise robustness. Materials and Methods: In this retrospective analysis of prospectively acquired data (2007-2017), we developed and validated a deep learning-based PRM approach using paired CT scans from 8,972 tobacco-exposed COPDGene participants ([&ge;]10 pack-years; mean age 60.1 {+/-} 8.8 years; 46.5% women), including controls with normal spirometry (n = 3,872; controls), PRISm (n = 1,089), GOLD 1-4 COPD (n = 4,011). Data were stratified into training, validation, and testing sets (24:6:70). PRMD extracts translation-invariant image features using a wavelet scattering network and applies a subspace learning classifier to classify voxels as emphysema or non-emphysematous air trapping (fSAD). PRMD was compared with conventional density-based PRM for voxel-wise agreement, correlation with pulmonary function, robustness to noise, and sensitivity to misregistration using Pearson correlation, Bland-Altman analysis, and paired t tests. Results: PRMD achieved 95% voxel-wise agreement with standard PRM (r = 0.98) while demonstrating significantly greater robustness under noise. PRMD showed stronger correlations with FEV1; (emphysema: r = - 0.54; fSAD: r = - 0.51; P < 0.0001) than standard PRM (r = - 0.42 for both; P < 0.0001). Under simulated high-noise conditions, standard PRM overestimated disease by ~15%, whereas PRMD limited error to < 5% (P < 0.001). Conclusion: PRMD provides an interpretable, feature-driven and noise-resilient alternative to traditional PRM for emphysema and fSAD classification, enhancing the reliability of CT-based COPD phenotyping for multi-center studies and low-dose imaging applications.

Injectable biomaterials with aligned microstructures play a critical role in tissue engineering and drug-delivery applications where control over the position and orientation of cells and nano/micron-scale architectures enhance intervention efficacy. Patients are often subject to MRI scans; for patient safety and treatment efficacy, we investigated the effects of MRI on a biomaterial treatment consisting of aligned magnetic microstructures being developed for guiding cell growth. Under MRI exposure, potential movement of aligned structures could be detrimental to nearby cells, and potential MRI-induced heating could adversely affect traumatized tissue. In this work, the alignment state and heat conduction of such a treatment were studied using a 9.4 T preclinical MRI. The treatment comprises short magnetic rod-shaped polycaprolactone fibers (rods) with embedded magnetic nanoparticles in a surrounding hydrogel (gelatin methacrylate), with rod alignment observed before and after a 45-minute MRI scan. No change in rod alignment state was observed, and no heat generation was measured. A theoretical framework was developed which supports the experimental observation that the biomaterial is stable under MRI. This work can be extended to other biomaterial systems with aligned architectures used in tissue engineering applications such as spinal cord, muscle and tendon.

International guidelines for low-frequency electromagnetic field exposure (LF EMF) are primarily intended to prevent substantiated adverse effects. In the frameworks, limits on internal electric fields are linked to external exposure levels through computational dosimetry. However, the relationship between internal electric fields and these adverse effects remains incompletely understood. In particular, current approaches often overlook the morphological complexity and diversity of cortical neurons, which may limit the realism of neuronal activation estimates used to support these assessments. This study evaluates LF EMF-induced neural activation using 25 morphologically realistic neuron models spanning all cortical layers, embedded within 11 detailed human head models. The internal electric fields were simulated for uniform magnetic field exposures (100 Hz-100 kHz) along the three anatomical directions, and excitation thresholds were computed using a multi-scale framework combining voxel-based dosimetry with biophysical neuron simulations. A real-world exposure scenario involving a child near an acousto-magnetic article-surveillance deactivator was also analyzed. Thresholds varied across cell type, morphology, cortical location, subject anatomy, frequency, and exposure direction, with L2/3 pyramidal, L4 basket, and L5 thick-tufted pyramidal cells showing the lowest thresholds. Despite this variability, all simulated thresholds were conservative with respect to the basic restrictions and dosimetric reference limits set by IEEE ICES and ICNIRP. The smallest margin occurred at 100 kHz, where the threshold remained a factor of 2.8 above the corresponding limit. These findings indicate that current LF EMF exposure limits remain conservative when evaluated using highly detailed, morphology-based CNS activation models.

Conflicting evidence on scatter correction (SC) methods plagues quantitative myocardial perfusion SPECT (MPI), hindering standardized clinical protocols. This simulation study, utilizing the SIMIND Monte Carlo program and a highly realistic 4D XCAT phantom, systematically evaluates Dual Energy Window (DEW, with k=0.5) and Triple Energy Window (TEW) SC techniques. We uniquely investigate their performance across various photopeak window widths (2, 4, and 6 keV) and novel overlapped/non overlapped configurations specifically for Tc 99m MPI parameters largely unexplored in realistic cardiac models. Images were reconstructed with OSEM under uncorrected (UC), SC, and combined attenuation and scatter corrected (ACSC) conditions. Quantitative analysis focused on signal to noise ratio (SNR), contrast to noise ratio (CNR), defect contrast, and relative noise to background (RNB). Our findings consistently show ACSC's superior performance in CNR, SNR, and defect contrast, confirming its critical role. Interestingly, SC alone reduced noise but compromised defect contrast relative to UC, highlighting a potential trade-off without attenuation correction. Crucially, this study reveals minimal influence of photopeak window width and overlap configuration on image quality, and no significant difference between DEW and TEW across most metrics. These results provide essential evidence for optimizing quantitative MPI protocols, suggesting that for Tc 99m, the choice between DEW and TEW, and specific window settings, may be less critical than ensuring robust attenuation correction.

Background: Even for experienced operators, endovascular treatment of unruptured intracranial aneurysms involves intraoperative uncertainty that may lead to adjustments in strategy, prolong the procedure, and potentially cause inefficiency and device waste. This study aimed to evaluate whether pre-procedural testing (PPT) of endovascular treatment using patient-specific models was associated with increased operator confidence and perceived clinical utility, including improvements in procedural efficiency and reduced resource waste. Methods: We enrolled a cohort of patients who underwent PPT before endovascular treatment for complex unruptured intracranial aneurysms and compared their outcomes with a control group treated without PPT. The primary outcome was the Training Fidelity Score, a composite of three operator-reported Likert items defined a priori. Secondary outcomes included perceived clinical utility, intraoperative strategy changes, procedural time, radiation exposure, device waste and safety. Results: A total of 85 patients met the inclusion criteria (PPT=40; control=45). The Training Fidelity Score was high across the PPT group (median, 4.33/5). Perceived clinical utility was high and further increased significantly after the procedure. A significant reduction was observed in intraoperative strategy changes, with no changes recorded in the PPT group, compared to 6/45 in the control group (RR 0.09; p=0.027). Reductions in treatment time, radiation exposure and device waste were also noted. Conclusion: PPT using patient-specific models was associated with increased operator confidence, fewer intraoperative strategy changes, improved procedural efficiency, and reduced device waste without compromising safety. These findings support its use in pre-interventional preparation, but require prospective multicenter validation.

BackgroundChemokine receptor type 5 (CCR5) is expressed on hepatic stellate cells (HSCs), which, together with fibroblasts, are major producers of extracellular matrix during liver fibrosis. Leronlimab is a humanized IgG4{kappa} monoclonal antibody that binds to CCR5. The objective of the present study was to evaluate the antifibrotic effects of leronlimab in three independent preclinical studies using two mouse models of liver fibrosis. MethodsIn STAM (Stelic Animal Model) model 1, leronlimab was administered at doses of 5 or 10 mg/kg/week for 3 weeks. STAM model 2 was conducted as a confirmatory study to validate the antifibrotic effect observed with the 10 mg/kg/week dose in STAM model 1. In a third study, a carbon tetrachloride (CCl)-induced liver fibrosis mouse model was used to evaluate leronlimab administered at 10 mg/kg/week for 3 weeks. An isotype-matched control antibody was included in all studies for comparison. Evaluations included liver enzymes and histological assessment of liver fibrosis. ResultsIn STAM model 1, leronlimab at 10 mg/kg/week significantly reduced fibrosis area compared with the isotype control (p = 0.0005). These findings were confirmed in STAM model 2 (p < 0.0001). Consistent antifibrotic effects were also observed in the CCl-induced liver fibrosis model (p = 0.0006). ConclusionsCollectively, these preclinical results demonstrate that CCR5 blockade by leronlimab is associated with a significant reduction of established liver fibrosis in multiple mouse models and support further evaluation of leronlimab as a potential therapeutic option, either as monotherapy or in combination regimens, for chronic liver diseases with fibrosis.